We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Personal Screen | PSP | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.085 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.085 | 0.085 |
| Top Posts |
|---|
Posted at 19/1/2011 18:41 by hamilton I don't know, I received some info about a vote being required, but letter had no return envelope or voting slip. The last suggestion (which I voted against) was to repay creditors (who appear by name to be the directors and their relatives)all remaining funds from the company and leave us investors with nothing. |
Posted at 17/8/2007 20:37 by hamilton I have been an investor in GON for 7 years, I don't trust him and I think his little brother (Simon) is incompetant. |
Posted at 11/2/2007 22:27 by stan36 Tried the PSP, Website does not work! I emailed them a while ago offering my IT company to do the website for virtually nothing but no response! Looks like they are using some amateur who can't even put a holding page in place. How can they expect to be taken seriously by investors? |
Posted at 24/1/2007 11:42 by tinker tailor Here is a little research from a few months back which makes an interesting read for prospective investors.New Issues Examined, by Oliver Haill Companies: AGI ECG PSP 13/03/2006 Soon after carbon credits player EcoEnergy secured its new funds (see page 11) Dublin-based pharmaceuticals outfit AGI Therapeutics reeled in £29.2 million, money that will be devoted to six 'product candidates' (five of which are in Phase II trials) it hopes will be able to treat such uncomfortable disorders as irritable bowel syndrome, functional dyspepsia, ulcerative colitis and gastro-esophageal reflux disease. At 86.5p the company, which obviously still has much to prove, is valued at £58 million. However, I found the arrival of another gut-focused health sector player, Personal Screening, which made one of the smallest AIM fundraisings last month, more easily digestible. This former OFEX tiddler is a supplier of self-test medical kits for detecting health and medical conditions such as bowel and prostate disorders, diabetes, high cholesterol, and the menopause. With the help of broker share price Angel and adviser Nabarro Wells, it pulled in £795,000 net at 1p on its journey to AIM's shores. The shares now stand at 1.81p and value it at £2.61 million. Executive chairman Michael Scorey, whose previous chairmanship of private healthcare business Clinovia saw it sold in 2003 for £45 million and whose last AIM-listed chairmanship, Omnicare, was sold in 1997 to US-owned Allied Healthcare, told me that Personal Screening was a 'bit of a bag of worms' operating in a cut-throat subsector when he arrived in 2004. However, very propitiously for the company (and presumably why it was brought to market) the marketing and distribution of these tests became controlled by European legislation that year and, laughs Scorey, 'in a stroke took away all our competition'. A unique position... 'We're in a unique position to exploit this market,' brags Scorey. 'A lot of our past competitors, who sold just to hospitals, are coming to us to sell their kits in the retail market.' PS's nine CE-approved kits are sold in pharmacies, on the internet and by mail order. Its last results, for the six months to last June, saw pre-tax losses cut from £563,000 to £52,000. Costs have been cut and new IT systems introduced. 'This means we are able to increase sales volumes with very little associated increases in overheads,' says Scorey 'and this should hopefully be a fairly rapid route to easy profits.' ...in a growing market This health sub-sector is expanding well, argues Scorey, as it has strong state support and a market in which people are becoming more aware of self-treatments and the benefits of supplements and self-testing products. Indeed, the Government's recent announcement of a bowel-cancer screening programme for 60-to-70 year olds was a contributory factor in increasing mail order sales. People not in this age bracket but who still considered themselves at risk were able to buy their own screening kits, demonstrating the growth of the home health culture. The UK market for over-the-counter medicines was £2 billion in 2004 and legislative changes to lighten the load on GPs have led to pharmacists being incentivised with higher rates of pay for the services they offer. Significantly for Personal Screening, offering self-test medical kits counts as a service. Making the kits even more alluring is that they are likely to result in repeat business for pharmacists' over-the-counter medicine. Elsewhere, the company has signed a deal with 50 Holland & Barratt health food stores, which are similarly motivated as they sell supplements that alleviate many of the tested complaints. The placing funds are to be used to beef up PR and marketing efforts, as Scorey sees these as the most effective way to increase visibility with the public. Looking further ahead, the next stage of growth is in expanding the range of tests, with drug testing being mooted and possibly even a move into pet screening for diabetes in dogs and chlamydia in cats! |
Posted at 24/1/2007 08:47 by mchapman do you think this stock will ever make money. Can you see it reaching 2p in the short term I am finding it difficult to get information on this company, their website for investors is useless |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
